CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
Follow CRMD
CorMedix Inc (CRMD) P/E ratio
As of 16 October 2026, CorMedix Inc (CRMD) trades at a P/E ratio of 3.0×. Over the past ten years it has ranged from 0.0× (March 2025) to 69.0× (June 2025); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 5.3× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 3.3× | 13.69% |
| Mar 2026 | 2.9× | (45.56%) |
| Dec 2025 | 5.3× | 1.81% |
| Sep 2025 | 5.2× | (67.27%) |
| 37 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| CRMD CorMedix Inc | 3.0× |
| ZVRA Zevra Therapeutics, Inc. compare | 10.5× |
| VALN Valneva SE Sponsored ADR compare | 59.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)